The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.02
Ask: 5.76
Change: 0.00 (0.00%)
Spread: 0.74 (14.741%)
Open: 5.76
High: 0.00
Low: 0.00
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results

Fri, 23rd Dec 2022 17:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

SulNOx Group PLC - London-based green technology company - Raises around GBP760,000 via placing and subscription of new shares at 11.5 pence price. Says largest shareholder Nistad AS invests further GBP80,000 to hold 13% in equity at SulNox. Follows announcement from yesterday which proposed fundraise to raise a minimum of GBP750,0000. "Despite difficult market conditions, we are pleased to have received institutional investor backing for SulNOx as an ESG, energy transition company with tremendous potential from reducing fossil fuel consumption and emissions across the globe," says Chief Executive Officer Ben Richardson. "Following the fundraising, SulNOx will have a runway to deliver increasing revenues and be able to accelerate our growth plans through 2023."

----------

Cindrigo Holdings Ltd - London-based clean energy producer - Reaches agreement with Danir AB, its largest shareholder and creditor, to provide new funding and restructure short-term debt of GBP4.3 million into long-term convertible loans. Danir provides additional loan funding of GBP750,000, following BK Fortuna AS's reported failure to provide agreed funding to Cindrigo, as announced on September 30. Says additional Danir funding is via 24-month convertible loan with a 5% interest rate per year. Says this loan is convertible into Cindrigo shares from 60 days after the company is readmitted to listing, with conversion price equal to the higher of either a 25% discount to the 30-day volume-weighted average share price or the minimum price per share of 125 pence. Existing GBP3.8m debt funding from Danir will be restructured and replaced by issue of new 10-year zero coupon convertible loan notes with a conversion price of 15p per share. Can be converted for a maximum of 25.3 million new Cindrigo shares.

----------

Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 trial in the European Respiratory Journal Open Research. Says while Sprinter trial does not meet the primary endpoints of discharge from the hospital and recovery, there is an encouraging signal in reduction in the relative risk of progression to severe disease or death with 35 days. Says SNG001 is well tolerated, as shown in previous clinical trials. Chief Scientific Officer & Lead Author Phillip Monk says: "The results from the SG016 phase 2 and the Sprinter trial of SNG001 in hospitalised patients, and the Activ-2 trial in the home setting, suggest that SNG001 may be preventing progression to severe disease. With these data, we remain confident in the potential of SNG001 as a broad-spectrum antiviral for high-risk patient populations infected with respiratory viruses including influenza and RSV and are focused on its continued clinical development." Says SNG001 is not approved for use anywhere in the world.

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Says it expects to achieve an average gross daily production rate of around 90 million standard cubic feet per day for 2022, compared to previous guidance of between 75MMscf/d and 85MMscf/d. As of Monday, current production levels are steady at a supply-constrained 90MMscf/d, below current demand nominations of 95MMscf/d from its key offtaker the Tanzania Petroleum Development Corp. Says Mnazi Bay joint venture is undertaking an infield workover and perforation programme, aiming to meet gas demand nominations in 2023. Hopes production levels will reach 90MMscf/d from late 2024 until at least 2027. Cash is USD30.0 million on December 1, while joint venture capital expenditure budget for 2023 is USD13.5 million.

----------

SEEEN PLC - London-based media and technology platform - Raises around GBP2.6 million via open offer of 523,887 shares. Says net proceeds are intended to bolster company's sales and marketing team, alongside investing into technology development projects to support planned next stage of growth.

----------

Dolphin Capital Investors Ltd - Cardiff, Wales-based investor in high-end resort developments in the eastern Mediterranean - Completes the EUR17.9 million disposal of its entire interest in the One&Only at Kea Island project. Prior to sale, Dolphin was 67% owner of Single Purpose Vehicle Ten Ltd, which owned 50% of OOKI, giving Dolphin Capital an effective 33% equity interest in OOKI. Receives EUR900,000 of sale proceeds on December 5 as an advance payment. Receives the remaining EUR17.0 million balance on completion. Around EUR13.0 million of the disposal proceeds used to repay its existing loan facility by December 31, which Dolphin Capital drew down in June and July. Says all debt has now been fully repaid.

----------

Curtis Banks Group PLC - Bristol-based financial services company - Says Nucleus Financial Platforms Ltd completes its due diligence amid advanced discussions over a possible offer for the entire share capital of Curtis Banks. Says both parties are close to agreeing transaction. Extends deadline for nucleus to announce offer to January 9 from Friday. Follows announcement of a potential takeover on November 25.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
18 Jun 2020 09:12

Synairgen expands Covid-19 trial nationwide

(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.

Read more
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
26 May 2020 13:55

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
29 Mar 2020 21:00

Sunday share tips: Synairgen, Hollywood Bowl

(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.

Read more
29 Mar 2020 20:57

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times

Read more
26 Mar 2020 14:26

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

Read more
26 Mar 2020 06:58

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Read more
18 Mar 2020 18:42

Britain's Synairgen gets green light for coronavirus drug trial

By Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...

Read more
18 Mar 2020 16:59

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Read more
18 Mar 2020 11:17

Synairgen to begin trial of potential Covid-19 therapy

(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.

Read more
1 Oct 2019 13:42

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Read more
27 Sep 2019 13:32

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Read more
24 Jul 2019 12:58

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

Read more
9 Jul 2019 09:26

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.